Business Wire

VOI

16.3.2020 08:02:10 CET | Business Wire | Press release

Share
EY Report on Micromobility Shows VOI’s Latest Scooters Have 71% Lower Impact on the Environment

Micromobility. Moving Cities into a Sustainable Future finds that Voi has reduced emissions by 71% over a year on e-scooters used in Paris by introducing best-practice measures and a new scooter model with a swappable battery.

  • Voi’s Paris scooters now produce 35g CO2 equivalents per person per kilometre, on par with many public transport options
  • Swappable battery scooters and cargo bike operations helped achieve a 51% reduction in emissions
  • Voiager 3 - the latest Voi model with a swappable battery - is expected to have a 24 month lifespan
  • The average emission level of new cars in the EU is 120.4g CO2/km

The report also finds that:

  • E-scooters are being taken up at 4 x the rate of e-bikes
  • There are over 20 million users of e-scooters across Europe
  • E-scooters have accumulated over 300 million trips globally in two years
  • Since launched in California in September 2017, e-scooters have reached 626 cities across 53 countries
  • 63% of Voi’s users have combined e-scooters with public transport

Please see below a statement from Voi’s co-founder and CEO Fredrik Hjelm to go with the EY report and a link to the report Micromobility. Moving Cities into a Sustainable Future here .

“Fundamental to Voi’s mission has been our belief that e-scooters and micro mobility can transform the way that people live, work and move through cities. We are delighted to see that EY also recognises the huge benefits that e-scooters could bring to cities and their potential to transform mobility options. In particular we are proud that our efforts to reduce emissions from our Paris operations have demonstrated that e-scooters can be just as sustainable an option as public transport, and produce a fraction of the emissions of new cars. Using insight from real-world data and interviews with city officials, this report shows how e-scooters are making the biggest impact, and where work still needs to be done.”

“We're under no illusion that e-scooters are the silver bullet when it comes to sustainable cities. Nevertheless the improvements we have made to our fleet and the supply chain are already shifting the dial. We very much welcome the report’s conclusion that e-scooters offer unprecedented potential but only when there are clear regulations that foster responsible and sustainable behaviour."

John Simlett, EY’s Global Future of Mobility Leader, says:

“Micromobility is here to stay, reducing emissions as well as relieving pressure on public transport systems, but cities and providers need to work together to seize this opportunity.

“In order to ensure that it takes its rightful place in the urban mobility ecosystem of tomorrow, the next phase of development in micromobility needs to be handled in a more collaborative, integrated and responsible way. This will require clear regulations on responsible and sustainable use, and increasing public access to micromobility infrastructure.”

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release

Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release

Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release

Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release

Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye